St. Jude Children’s Research Hospital scientists show that IRGB10, an essential protein induced by the signaling protein interferon, is needed to activate danger-sensing proteins in the cytoplasm of cells.
St. Jude Children’s Research Hospital scientists have discovered a previously unrecognized form of macrophage in mice; the immune cells survived chemotherapy and protected against life-threatening lung infections.
National Institutes of Health funding will allow physicians and researchers to help sickle cell patients in Memphis and surrounding communities improve access and adherence to hydroxyurea treatment
The newly expanded Methodist Comprehensive Sickle Cell Center at Methodist University Hospital will strengthen research into sickle cell disease and serve the growing needs of sickle cell patients in the Memphis area
Researchers led by St. Jude Children’s Research Hospital have demonstrated that flu vaccines with adjuvants don’t work as well in obese mice; results highlight urgent need to understand vaccine response in obese humans.
Research from the Childhood Cancer Survivors Study has identified distinct profiles of psychological symptoms in adolescent cancer survivors; a finding that is expected to advance mental health screening and treatment.
The multifunctional “scaffold” protein Alix is essential for maintaining the integrity of the cell cytoskeleton and the blood-cerebral spinal fluid barrier in the choroid plexus of the mouse brain; animals lacking Alix develop hydrocephalus.
The Department of Pathology has been accredited by The College of American Pathologists (CAP), a Centers for Medicare and Medicaid Services (CMS)-approved accreditation authority.
St. Jude Children’s Research Hospital reports that higher blood concentrations of methotrexate during cancer treatment are associated with brain changes and impaired executive function in survivors of pediatric leukemia.
St. Jude Children’s Research Hospital investigators report promising preliminary results at the annual meeting of ASCO for an experimental monoclonal antibody when combined with chemotherapy for newly diagnosed patients.
New research from St. Jude Children’s Research Hospital shows support interventions by child life specialists decrease sedation use and costs associated with cranial radiation therapy.
St. Jude Children’s Research Hospital used advanced pharmacologic modeling and simulation for the first time to translate promising laboratory results into a phase I clinical trial for pediatric brain tumor patients.
St. Jude Children’s Research Hospital scientists report the first evidence that a pathogen-specific antibiotic was less disruptive to the gut microbiome than broad-spectrum antibiotics.
Research led by St. Jude Children’s Research Hospital could help to expand precision medicine by identifying cancer patients who should avoid the chemotherapy drug asparaginase.
Early results suggest novel gene therapy is safe and effective for treatment of inherited immune disease, according to St. Jude Children’s Research Hospital and the National Institute of Allergy and Infectious Diseases.
Research led by St. Jude Children’s Research Hospital scientists may set the stage for new approaches to control or prevent the inflammation and tissue damage associated with the chronic autoimmune disorder lupus
St. Jude Children’s Research Hospital scientists have revealed new details about how a promising class of anti-influenza drugs blocks the virus from replicating.
St. Jude Children’s Research Hospital scientists have identified a mechanism that might explain the link between maternal infections during pregnancy and cognitive problems in children; findings may impact clinical care.
St. Jude Children’s Research Hospital scientists show that BCL-2 ovarian killer or BOK triggers mitochondrial cell death; process regulated by stability of the BOK protein
Research led by St. Jude Children’s Research Hospital has advanced understanding of how the nucleolus is assembled through a process called liquid-liquid phase separation and has identified a protein that plays key role.
St. Jude Children’s Research Hospital scientists have discovered that an enzyme antibiotics rely on to kill bacteria also promotes survival of pneumococcus and sets the stage for serious, invasive infections
Research led by St. Jude Children’s Research Hospital and the German Cancer Research Center shows molecular analysis is likely to improve classification and diagnosis of a rare brain tumor and advance precision medicine
St. Jude Children’s Research Hospital has received a unanimous vote of approval from the Tennessee Higher Education Commission for the opening of a new graduate school of biomedical sciences.
St. Jude Children’s Research Hospital scientists discover a novel strategy that aggressive sarcomas use to promote drug resistance and cancer’s spread plus evidence of how to reverse the process.
Research led by St. Jude Children’s Research Hospital has identified genetic variations in young leukemia patients that are associated with an increased incidence of osteonecrosis, a serious cancer treatment side effect
St. Jude Children’s Research Hospital scientists capitalize on technological advances to lay the groundwork for drug development against “disordered” proteins that play key roles in human health and disease
St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project completes the most comprehensive analysis yet of the role genes associated with cancer predisposition play in childhood cancer
Research led by St. Jude Children’s Research Hospital investigators found evidence that variations in the ETV6 gene may play a significant role in the inherited predisposition to pediatric acute lymphoblastic leukemia.
St. Jude Children’s Research Hospital study shows computer-based cognitive training is as effective as medication for improving working memory and attention in childhood cancer survivors with cognitive deficits
St. Jude Children’s Research Hospital scientists advance understanding of intrahepatic cholestasis of pregnancy, a liver disorder that leaves infants born to affected mothers at risk for severe respiratory distress
St. Jude Children’s Research Hospital scientists identify a mechanism that plays a key role in cellular organization and function and also offers a possible new treatment strategy for ALS and other degenerative disorders
Scientists led by St. Jude Children’s Research Hospital have identified how mutations in the IKZF1 gene contribute to a high-risk leukemia subtype and drugs that may enhance the effectiveness of targeted therapy
St. Jude Children’s Research Hospital and University of Massachusetts Medical School uncover the mechanism underlying the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia
Jinghui Zhang, Ph.D., an international expert in the analysis of genomic data, will lead the growth of innovative effort in newly dedicated space supported by Brooks Brothers
Research led by St. Jude Children’s Research Hospital reveals how the tumor suppressor protein p53 works in the cytoplasm to trigger death via apoptosis and identifies a potential cancer treatment strategy.
A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib; St. Jude Children’s Hospital led the Pediatric Brain Tumor Consortium trials in children and adults.
Researchers led by St. Jude scientists have discovered evidence for such characteristic features of malignant masses by analyzing the health records of 131 patients seen at St. Jude and Le Bonheur Children’s Hospital.
By growing two types of stem cells in a “3-D culture” and measuring their ability to produce retinal cells, a team lead by St. Jude Children’s Research Hospital researchers has found one cell type to be better at producing retinal cells.
The research not only reveals which stem cell type might be better for treating retinal degeneration, but it also demonstrates a standardized method for quantifying the effectiveness of different stem cells for such therapies.
Scientists at St. Jude Children’s Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer. They found that AIM2 deficiency causes uncontrolled proliferation of intestinal cells.
Researchers led by St. Jude Children’s Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. The findings appear today in the scientific journal Science Translational Medicine.
J. Paul Taylor, M.D., Ph.D., of St. Jude Children's Research Hospital, has been recognized as one of the nation’s leading biomedical researchers by the Howard Hughes Medical Institute
Childhood cancer survivors – especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids – are 14 percent more likely to be obese than their healthy peers. The St. Jude Children’s Research Hospital study appears today in the journal Cancer.
Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children’s Research Hospital scientists led the study, which appears today in the journal Cancer Cell. The genes – TAF12, NFYC and RAD54L – are involved in DNA repair and regulation. Researchers showed that CPC often has at least one extra copy of each gene and demonstrated that the genes work cooperatively to launch and sustain the tumor.
St. Jude Children’s Research Hospital scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor. The findings appear today in the Journal of Molecular Biology. The findings involve the DDX3X gene. In 2012, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma. Such treatments target the genetic mistakes that give rise to the brain tumor’s four subtypes.
Researchers led by St. Jude Children’s Research Hospital scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases. The findings appear online today in the scientific journal Nature Genetics.